Vivek Subbiah: Super thrilled to share our paper – Variant of allele frequency: a decision-making tool in precision oncology?

Vivek Subbiah, Chief, Early-Phase Drug Development, Sarah Cannon Research Institute, made the following post on LinkedIn:

“Hot off the press: Super thrilled to share our paper – Variant of allele frequency: a decision-making tool in precision oncology? – published in a Cell Press journal Trends in Cancer !
An absolute delight to collaborate with the amazing Giuseppe Curigliano & his terrific team among many others.

PrecisionMedicine Sarah Cannon Research Institute.
A great pre-read before ESMO23 and MAP23 meetings”

For details click here
Source: Vivek Subbiah / LinkedIn